Vestronidase Alfa-vjbk Injection (MEPSEVII)

Mepsevii (vestronidase alfa‑vjbk) is covered only for the FDA‑approved indication of mucopolysaccharidosis type VII (MPS VII) and is not covered for non‑FDA‑approved uses. Coverage requires lab or molecular genetic confirmation of beta‑glucuronidase deficiency, prescription or consultation by a geneticist, endocrinologist, metabolic disorder or lysosomal storage disorder specialist, documentation of dosing (up to 4 mg/kg IV no more frequently than every 2 weeks), applicable safety criteria, and approvals are granted for up to 12 months.

"Approval duration: 12 months."

Sign up to see full coverage criteria, indications, and limitations.